Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose Derived Stem Cells

Business Wire,  June 27, 2007  

Tags: banking, stem-cell, University of Pittsburgh

• E-mail
• Print
• Link

SAN DIEGO -- The University of Pittsburgh School of Health Sciences issued the following study and press release, "Scientists Culture Blood-Forming Stem Cells from Human Fat Tissue," June 15, 2007, Science Daily: "Researchers at the University of Pittsburgh School of Medicine have successfully isolated and cultured human hematopoietic stem cells from fat, or adipose tissue, suggesting that they have found another important source of cells for reconstituting the bone marrow of patients undergoing intensive radiation therapy for blood cancers."

"This recent announcement by Researchers at the University of Pittsburgh School of Medicine that hematopoietic, or blood forming stem cells, can be isolated from fat, or adipose tissue, could have a major impact on the acceptance of the medical community and the public to store stem cells from this abundant source," said Dr. Geoffrey O'Neill, Chief Scientific Advisor of Bio-Matrix Scientific Group Inc.

Until now, banking of fat derived stem cells has focused on future regenerative medicine procedures such as heart muscle and bone repair, but these findings could provide compelling reasons for millions of individuals to store stem cells from fat.

"Currently cord blood banking provides a once in a lifetime opportunity to store hematopoietic stem cells at birth, but these new findings could provide millions of individuals, young and old, the opportunity to store blood forming stem cells that can be used today to treat a variety of life threatening diseases," stressed Dr. O'Neill.

Furthermore, Dr. O'Neill stated that fat may ultimately prove to be a unique resource for many types of stem cells, a fact that is based on the physiological nature of fat as an important organ, since it has the ability to expand and contract rapidly to nutritional signals which may indicate an important requirement and source for stem cells in this tissue.

Currently, Bio-Matrix is working towards opening its 15,000 square foot Stem Cell Banking facility. The focus of this facility will be the banking of Adipose (Fat) derived stem cells.

Dr. Geoffrey O'Neill received his Ph.D. in Immunology from the University of Glasgow in 1973. In 1974, he undertook post-doctoral training under the guidance of Dr. Robert A. Good (who performed the first bone marrow transplantation in a patient with immunodeficiency) at Memorial Sloan-Kettering Cancer Center in New York. Dr. O'Neill's field of study at Sloan-Kettering was transplantation immunobiology.

Dr. O'Neill has over twenty five years' experience in his field, achieving recognition from his colleagues as the recipient of the Jean Julliard Prize for Outstanding Research from the International Society of Blood Transfusion and International Society of Hematology, presented in Budapest, Hungary. He also received the JM Foundation Award, New York, for innovative research.

About Bio-Matrix Scientific Group

Bio-Matrix Scientific Group Inc. (www.BMSNonline.com) is a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market. The company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation. Bio-Matrix' new 15,000 sq. ft. state-of-the-art facility, located in the heart of San Diego's biotechnology corridor, plans to open in September 2007. It will house Bio-Matrix' secure Cryogenic Stem Cell Bank, three research laboratories, aseptic cellular/tissue class 10,000/100 processing laboratory, hematology, microbiology and flow cytometry laboratories. The facility plans to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.

DISCLAIMER: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

COPYRIGHT 2007 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning